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Substrate-Based Inhibitors of Peptidylglycine á-Amidating
Monooxygenase (PAM) as Anti-Proliferative Drugs for Cancer
Geoffrey H. Chew
ABSTRACT
C-Terminal glycine-extended prohormones are enzymatically converted to áamidated peptides, by peptidylglycine á-amidating monooxygenase (PAM). PAM is a
bifunctional enzyme with two catalytic domains: peptidylglycine á -hydroxylating
monooxygenase (PHM) and peptidylglycine peptidylglycineaminoglycolate lyase (PAL).
PAM has a significant role in the proliferation of androgen-independent prostate
cancer. Thus, the inhibition of PAM could halt cancer growth. Hippurate and hippurate
analogs were used as lead compounds for developing inhibitors for PAM. The hippurate
analogs exhibiting the highest affinity to PAM (lowest inhibition constant) did inhibit the
growth of human androgen-independent prostate cancer DU 145 cells.

vi

Chapter One
Literature Review

Peptidylglycine á-amidating monooxygenase
Approximately 50% of all mammalian hormones are amidated, and play
important roles in biological systems. Many hormones, such as human growth hormonereleasing factor (GRF), are only active in the amidated form (Merkler 1994). C-Terminal
glycine-extended prohormones are enzymatically converted to á-amidated peptides, by
peptidylglycine á-amidating monooxygenase (PAM). PAM is the only known enzyme
that performs this chemistry (Eipper 1988).
PAM enables the oxidative cleavage of inactive C-terminal glycine-extended
prohormones to active á-amidated peptides and glyoxylate. PAM is a bifunctional
enzyme with two catalytic domains: peptidylglycine á-hydroxylating monooxygenase
(PHM) and peptidylamidoglycolate lyase (PAL) (Merkler, 1995). PHM catalyzes the
O2-, copper-, and ascorbate-dependent insertion of oxygen from an O2 molecule at the Cα
of the terminal glycyl residue to form a carbinolamide while PAL catalyzes the zincdependent dealkylation of the carbinolamide to the α-amidated peptide and glyoxylate
(Jaron, 2002) (Figure 1).
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Figure 1-The peptide amidation reaction as catalyzed by PAM. PAM is a bifunctional
protein comprised of two distinct catalytic entities: peptidylglycine á-hydroxylating
monooxygenase (PHM) and peptidylamidoglycolate lyase (PAL). Labeled nitrogens and
carbons were used in experiments to determine products of the reaction.

Early work performed using bifunctional PAM defined essential characteristics of
the peptide amidation reaction. Incubation of D-Tyr-Val-[glycyl-15N]-Gly with
bifunctional PAM yields D-Tyr-Val-[15N]-NH2 , which demonstrates the glycyl nitrogen
is retained in the final amide (Bradbury 1982). In a similar experiment, D-Tyr-Val-[14C]Gly was used as a substrate. The labeled carbon atoms were incorporated only into
glyoxylate. Eipper et al. (1983) showed that molecular oxygen, copper, and an electron
donor were required for the PAM reaction to occur. Metal chelators completely
abolished PAM activity that only could be restored upon the addition of copper -- at a
slight excess over the residual chelator concentration. The turnover of each glycineextended peptide to the α-amidated peptide requires the input of two electrons, which can
be donated from many different reductants. Ascorbic acid is the most efficient electron
donor, exhibiting the highest (VMAX/KM)app at constant peptide substrate concentration,
and is likely the reductant utilized by PAM in vivo (Merkler 1992). After the discovery
that PAM is bifunctional and that the C-terminal α-hydroxyglycine extended peptides are
intermediates in the amidation reaction, it was established that O2-, copper, and ascorbate
were only required for the PHM reaction. Figure 2 shows the 3D structure of PHM with
a bound substrate. Note the presence of two PHM-bound copper atoms, one on either
side of the binding pocket.
2

H2

Figure 2- 3D structure of PHM with bound substrate.

EPR studies performed by Freeman et al. (1993) demonstrated that PHM-bound
Cu (II) redox cycles from Cu (II) to Cu (I) back to Cu (II) during catalysis. All of the
copper ions before the addition of ascorbate are spin active. After the addition of
ascorbate, 95% is no longer spin active, which indicated that the Cu (II) is reduced to Cu
(I). After reaction with the substrate, Cu (I) reverts back to Cu (II).
PHM and dopamine â-monooxygenase (DBM) exhibit a number of catalytic
similarities. Both enzymes insert an oxygen atom from O2 into an inactivated C-H bond,
have a copper stoichiometry of two copper atoms per active site, and oxidize two
ascorbate molecules to semihydroascorbate per enzyme turnover. In addition to catalytic
similarities, the two enzymes have similar protein sequence (Figure 3) and expression
levels.
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Figure 3- Compared protein sequences of rat PHM and DBM using BlastP. There is 29%
identity and 41% positives.

Considerably less is known about the PAL reaction. Model studies indicate that
carbinolamide dealkylation is base-catalyzed (Bundgaard 1991). These data suggest that
an enzymatic base abstracts the hydroxyl proton to facilitate conversion to the amide and
glyoxylate. Another possibility is that a zinc-based hydroxyl is the enzymatic base; thus,
accounting for the zinc dependence of the PAL reaction (Bell 1997).
Using a set of glycine-extended peptides of the form N-dansyl-(Gly)4-X-Gly,
Tamburini et al. (1990) demonstrated that PAM could produce peptides terminating all
20 amino acid amides. The penultimate amino acid does have an effect on the kinetic
constants for á -amidation. The VMAX/KM value obtained for N-dansyl-(Gly)4-Phe-Gly
was 1140-fold higher then that obtained for N-dansyl-(Gly)4-Glu-Gly. The glycineextended peptides with a sulfur-containing or hydrophobic amino acid in the penultimate
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position exhibited the highest VMAX/KM values (Table 1). This result was critical in our
development of novel sulfur-containing hippurate analogs as PAM inhibitors.
X

KM
(µ M)

VMAX
(nmol/min/mg)

Relative
VMAX/KM

X

Phe
Tyr
Met
Ile
Trp
Val
Cys
Leu
His
Ala

4
5
7
20
58
49
11
54
41
334

50
40
23
55
58
48
10
22
10
50

1140
730
300
250
91
89
83
37
22
14

Ala
Asn
Arg
Gln
Ser
Pro
Lys
Glu
Gly
Asp

KM
(mM)
46
83
200
308
196
618
206
449
-

VMAX
(nmol/min/mg)
6
7
15
17
9
22
4
5
-

Relative
VMAX/KM
12
7.6
6.8
5.0
4.2
3.3
1.7
1.0
<0.4
-

Table 1- Kinetic parameter for N-dansyl-(Gly)4-X-Gly amidation

Replacement of the C-terminal glycine with any other D- or L-amino acid, with
the exception of D-alanine, did not support PAM catalysis. D-Alanine-extended peptides
are relatively poor PAM substrates, exhibiting VMAX/KM values that are ~0.1% of that
obtained for the corresponding glycine-extended peptides. Based on this finding,
hippurate and hippurate analogs were used as a lead compounds for developing inhibitors
for PAM.

The role of PAM in prostate cancer
Prostate cancer is the second leading cause of cancer death in males today. The
probability that a man will contract prostate cancer in his lifetime is reaching 100%
(Parker 1996). There are two basic types of prostate cancer: androgen-dependent and
androgen-independent (Bonkhoff 1993). Androgen-dependent prostate cancer cells have
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Graph 1- PAM activity in androgen-dependent (LnCaP)and androgen-independent (PC-3
and DU 145) prostate cancer cell lines.

many androgen receptors. When deprived of androgen, these cells die. Androgenindependent cells do not have these receptors and do not rely on androgen to proliferate
(Rocchi 2001). A common androgen-dependent cell line is LnCaP, and common
androgen-independent cell lines are PC-3 and DU 145. Androgen-dependent forms of
cancer can be effectively treated by therapeutic hormone deprivation (Kyprianou 1990),
but in most cases where androgen-dependent prostate cancer has been suppressed, it
remerges as an androgen-independent form. The pathway for this change is not known,
but it is thought that PAM has a role in the proliferation of the newly formed androgenindependent cancer. In androgen-independent strains of prostate cancer, there is a 3-fold
greater amount of PAM mRNA. There are also elevated PAM protein levels (Graph 1).

Graph 2- Effect of AM on cell growth of DU 145 prostate cancer cells.
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The specific activity of the PAM found in the androgen-independent cell lines is also
higher.
Adrenomedullin (AM), a growth-stimulating á-amidating peptide, is produced by
androgen-independent prostate tumors (Rocchi 2001). AM is only active in its amidated
form. Graph 2 shows the growth rates of DU-145 cells that have been treated with AM.
There is a significant increase in cell growth when AM is added. AM does not affect
androgen-dependent cells. It is thought that the amount of AM that can be used in these
cell lines are at their maximum, thus adding more peptide does not affect these cells
(Rocchi 2001).
N-(4-hydroxyphenyl) retinamide (4-HPR) is a known inhibitor of DU-145
OH

Me

Me

Me
E

Me
E

E

HN
E
O

Me

Figure 4- Structure of 4-HPR.

cells (Figure 4). It is thought that 4-HRP undergoes an oxidative pathway that generates
reactive oxygen species. These oxygen species are extremely dangerous to cells, since
they interrupt pathways by inactivating enzymes. The aminophenol ring and long alkyl
chain are key functional groups for drug-cell contact (Takahashi 2002). Aminophenols
such as p-methylaminophenol ( p-MAP), 4-aminophenol (4-AP), and paminoacetophenol (p-AAP) have also been shown to stop cell growth. Graph 3 shows
the effect of 4-HPR and several aminophenols on the growth of DU 145 cells.

7

Graph 3- Effects of 4-HPR on DU 145 prostate cancer cell growth. Cells were grown with
compound for 72 hours before counting. The clear squares represent control cells, the clear
triangles represent 4-HPR, the solid squares represent p-MAP, the solid circles represent 4AP, and the solid diamonds represent p-AAP.

Conclusion
Around 50% of all mammalian hormones have the C-terminal á-amidated
structure that PAM produces. PAM plays a critical role in the emergence of androgenindependent forms of prostate cancer. The experiments in the following chapters use
substrate-based inhibitors targeted for PAM. The kinetic constants were experimentally
detected and the most potent compounds were tested on prostate cancer cells to determine
if they would halt DU-145 cell proliferation.
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Chapter Two
Substrate-Based Inhibitors for PAM

INTRODUCTION
Inhibitors are substances that lower the rate of catalysis of an enzyme. Inhibiting
enzymes are one of the most common ways that organisms regulate their biological
processes. The binding specificity of a substance towards an enzyme can be determined
by studying the inhibition (Segel 1976). In many types of cancer, there are mutated
enzymes that cause the spread of the disease, thus inhibiting these enzymes is key to
halting cancer proliferation.

Enzyme Inhibition
Three types of inhibition have been described that account for the reversible
binding of one inhibitor molecule, I, to one enzyme molecule, E (Figure 5). For
competitive inhibition, the inhibitor and substrate, S, compete exclusively for E yielding
either the catalytically competent ES complex or the catalytically incompetent EI
complex (Figure 5a). Non-competitive inhibition involves the binding of I to E and ES to
producing both an EI binary complex and an ESI ternary complex. The affinity of I to E
and ES is described by two dissociation constants, Kis and Kii, respectively (Figure 5b).
If Kis equals Kii, the inhibition is usually referred to as non-competitive or pure noncompetitive inhibition. If Kis does not equal Kii, the inhibition is referred to as mixed9

type inhibition. Uncompetitive inhibition is the binding of I only to the ES complex to
generate the inactive ESI complex (Figure 5c). Segal (1976) details other inhibition
types, usually involving the reversible binding of more than one inhibitor molecule per
enzyme molecules. Such modes of inhibition are infrequently encountered.
kp

Ks

ES

E + S
+
I

E + S

Ki

a)

ES
+
I

E + P

Ki

c)

EI

ES
+
I

Kis

ESI

kp

Ks

E + S
+
I

E + P

Kii
αKs

b)

kp

Ks

E + P

EI + S

ESI

Figure 5- Diagram of a) competitive inhibition, b) non-competitve inhibition, and c)
uncompetitive inhibition

Irreversible inhibitors are well known in the enzyme literature and, most often,
involve the generation of an inactive enzyme species after the initial formation of the EI
complex (Figure 6). The mechanism outlined in Figure 6 can account for mechanismbased, suicide substrates, the chemical modification of active site resides, and slowbinding inhibitors (kinact <<< kp).
k inact

Ki

E + I

EI

(EI)inactive

Figure 6- Diagram of irreversible inhibition. For slow-binding inhibition, S and I compete for E
(similar to competitive inhibition) and kinact <<< kp.
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N-Benzoylglycine (Hippuric Acid) as Lead Compound
Tamburini et al. (1990) demonstrated that PAM preferred peptide substrates with
hydrophobic or sulfur-containing amino acids at the penultimate position. Hippurate is
an ideal candidate as an ideal lead compound for the development of small molecules
inhibitors of PAM for the following reasons: (a) hippurate is a known PAM substrate, (b)
hippurate contains a hydrophobic N-benzoyl group at a position analogus to the
penultimate amino acid in C-terminal glycine extended peptides, (c) numerous ringsubstituted hippurates and hippurate analogs are commercially available, (d) two sulfur
containing hippurate analogs were commercially available, and (e) targeted analogs of
hippurate that are not available commercially (with and without sulfur) are relatively
straightforward to synthesize.
Given these considerations, we have prepared and evaluated a library of
substituted hippurates and hippurate analogs as substrates and inhibitors. The inhibitors
with the highest affinity for PAM (lowest values of Kis and Kii) were then tested for antiproliferative behavior vs. prostate cancer cells in culture (Chapter 3).

Methods to Assay for PAM Activity
PAM converts C-terminal glycine-extended peptides to á-amidated peptides and
glyoxylate in a reaction that consumes O2 and reductant (Figure 1). Thus, PAM activity
can be measured by assaying for (a) the consumption of O2, (b) the consumption of
reductant, (c) the production of glyxoylate, and (d) the production of the á-amidated
peptide. These different assay methods have advantages and disadvantages and all have
been appropriately applied in the study of PAM. The two assay methods employed to
11

generate the data contained within this thesis were to measure PAM-dependent
conversion of N-dansyl-Tyr-Val-Gly to N-dansyl-Tyr-Val-NH2 by HPLC and to measure
the PAM-dependent consumption of O2 in the presence of an oxidizable substrate.
The PAM-dependent conversion of N-dansyl-Tyr-Val-Gly to N-dansyl-Tyr-ValNH2 has been extensively used in the Merkler laboratory (Merkler 1999). This assay is
sensitive, requiring relatively small amounts of enzyme and N-dansyl-Tyr-Val-Gly, and
can be carried in volumes <<1.0 ml, particularly important if the small amounts of
inhibitor are available*. However, this method is laborious, provides only a
discontinuous measure of [product] formed per unit time, and requires the availability of
an HPLC equipped with an autosampler, and an inline flow-through fluorescence
detector. The development of new HPLC separation methods and syntheses of substrate
and product standards are necessary to extend this assay method to other N-dansylated
(or otherwise fluorescently-lableled) PAM substrates.
The PAM-dependent consumption of O2 has also been extensively employed in
the Merkler laboratory (Merkler 1999). This method requires only an O2 electrode,
provides a continuous measure of [substrate] consumed per unit time, and is generally
useful for any oxidizable substrate. Unfortunately, this assay is less sensitive than
assaying for N-dansyl-Tyr-Val-NH2 production and requires considerable more PAM and
substrate. Furthermore, this system has an inherent background rate of O2 consumption

*

Non-fluorescent substrates that compete with N-dansyl-Tyr-Val-Gly for the
PAM active site behave as competitive inhibitors (Spector 1981). The Kis values
obtained using non-fluorescent substrates equal the KM. The PAM-dependent conversion
of N-dansyl-Tyr-Val-Gly to N-dansyl-Tyr-Val-NH2 is useful to determine KM values for
non-fluorescent substrates of limited availability or those that exhibit low VMAX values.
12

(from the O2 electrode and the presence of reductant and Cu(II) ions in the assay buffer)
that renders this method difficult to use with substrates of with low VMAX values.

EXPERIMENTAL PROCEDURES
Materials
MES buffer, N-dansyl-Try-Val-Gly, hippuric acid and S(thiobenzoyl)thioglycolic acid were from Sigma, sodium chloride, ethanol, Triton X-100,
HEPES buffer, acetonitrile, sodium acetate, sodium hydroxide, and trifluoroacetic acid
were from Fisher Scientific, sodium ascorbic acid was from Research Organics, copper
nitrate and isopropanol were from Acros, and catalase was from Worthington
Biochemical Corporation. N-Acetylglycine was from T.C.I. Oxygen monitor and
electrodes were from Yellow Spring Instrument. Signal amplifier was from Oriel and
assembled by Dr. R. Larsen (University of South Florida). N-Phenylhydantoic acid was
from Maybridge. (D,L)-Thiorphan was from BACHEM. 4-Ethylhippuric acid, N(phenylthiopropionyl)glycine, 4-propionylhippuric acid, N-(6-phenylhexanoyl)glycine,
N-(8-phenyloctanoyl)glycine, S-(4-methylthiobenzoyl)thioglycolic acid, S-(4methylthiobenzoyl)thioglycolic acid ethyl ester, S-(phenylthioacetyl)thioglycolic acid, S(N-phenylthiocarbamoyl)thioglycolic acid, S-(N-phenylthiocarbamoyl)-3mercaptopropionic acid, N-glycolic acid phenyl urethane, lauroyl-sulfanyl-acetic acid and
S-(3-phenylthiopropionyl)thioglycolic acid were from Dr. T. C. Owen (University of
South Florida). (Phenylthio)acetic acid and (2-nitrophenylthio)acetic acid were from Dr.
J. Vederas (University of Alberta). N-(Phenylthioacetyl)alanine and 4-cyano-4-methyl-4-
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thiobenzoyl-sulfanyl-butyric acid were from Dr. A. Lowe (University of Southern
Mississippi). HyperChem 7.5 was from Hypercube Inc.

High-performance liquid chromatography
N-Dansyl-Try-Val-Gly and N-dansyl-Try-Val-NH2 were separated using a
Hewlett Packard 1100 Series liquid chromatograph equipped with a quaternary solvent
delivery system, vacuum degasser, temperature controlled column compartment, and an
auto injector. A Keystone Scientific Operations Thermo Hypersil reverse-phase C18
column (100 mm x 4.6 mm, 5 µm particles, 120 pore) fitted with a Phenomenex C

18

Security Guard column was used for the separation. A Gilson Model 121 flurometer and
a Hewlett Packard 3392A integrator monitored separations. Hewlett Packard
ChemStation controlled the 1100 Series liquid chromatograph.
Bifunctional peptidylglycine α-amidating monooxygenase
Chinese hamster ovary cells that secrete recombinant type A rat medullary thyroid
carcinoma PAM into the culture media (Bertelsen, 1990) were grown in a Cellco
Cellmax-100 hollow fiber bioreactor (Matthews, 1994). The bifunctional enzyme was
purified as described by Miller et al. (1992) except that the final gel filtration step
(Superdex-200) was done using 50 mM Tris pH 8.0 and 100 mM NaCl. The amidation
of N-dansyl-Tyr-Val-Gly to N-dansyl-Tyr-Val-NH2 (Jones 1988) and UV detection at
280 nm were used throughout the enzyme purification to screen column fractions.

14

HPLC separation of dansylated compounds
N-Dansyl-Try-Val-Gly and N-dansyl-Try-Val-NH2 were separated on a reversephase C18 column (100 mm x 4.6 mm, 5 µm particles, 120 pore). The mobile phase for
the separation consisted of 100 mM sodium acetate, 55% deionized water and 45%
acetonitrile. The mobile phase was delivered at a flow rate of 1.2 ml/min. The injection
volume was 10 µl. The retention times of the N-dansyl-Try-Val-Gly and Dansyl-TryVal-NH2 were 1.3 and 2.35 minutes.

Determination of initial rates of N-dansyl-Try-Val-NH2 production as fixed N-dansylTry-Val-Gly concentration as a function of inhibitor concentration (Dixon analysis)
Reactions at 37 C we re initiated by the addition of PAM (0.05-0.09 ì g) into 500
ì l of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001 % (v/v)
Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu (NO3)2, 5.0 mM sodium ascorbate,
inhibitors (1.0-2000 ìM) and 8 µM N-dansyl-Try-Val-Gly. Aliquots of 50 µl were taken
at 5, 10, 15, 20, and 25 minutes. The reaction aliquot was quenched with 10 µl of 6 %
(v/v) trifluoroacetic acid in a HPLC microvial to terminate the PAM reaction. The
aliquots were assayed for N-dansyl-Try-Val-Gly and dansyl-Try-Val-NH2 on a reversephase C18 column (100 mm x 4.6 mm, 5 µm particles, 120 pore). The mobile phase for
the separation consisted of 100 mM sodium acetate, 55% deionized water and 45%
acetonitrile.

15

Determination of KM and VMAX values for N-dansyl-Tyr-Val-Gly as a function of inhibitor
concentration
Reactions at 37 C we re initiated by the addition of PAM (0.02 –0.03µg) into 500
ì l of 100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001 % (v/v)
Triton X-100, 10 µg/ml bovine catalase, 1.0 µM Cu (NO3)2, 5.0 mM sodium ascorbate,
N-dansyl-Try-Val-Gly (1.25-12.5 µM), and inhibitor (20-800 µM). Aliquots of 50 µl
were taken at 5, 10, 15, 20, and 25 minutes. The reaction aliquot was quenched with 10
µl of 6 % (v/v) trifluoroacetic acid in a HPLC microvial to terminate the PAM reaction.
The aliquots were assayed for N-dansyl-Try-Val-Gly and N-dansyl-Try-Val-NH2 on a
reverse-phase C18 column (100 mm x 4.6 mm, 5 µm particles, 120 pore). The mobile
phase for the separation consisted of 100 mM sodium acetate, 55% deionized water and
45% acetonitrile.

Determination of initial rates by oxygen consumption
In order to determine kinetic constants (KM and VMAX), reactions at 37 C were
initiated by the addition of PAM (0.03-0.06 µg) into 2700 ì l of 100 mM MES/NaOH pH
6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001 % (v/v) Triton X-100, 10 µg/ml bovine
catalase, 1.0 µM Cu (NO3)2, 5.0 mM sodium ascorbate, and substrate (3.0-2500 ìM).
VMAX values were normalized to controls ran at 11 mM N-acetylglycine. Rates were
monitored, recorded, and analyzed in Microsoft Excel.
In order to determine the Ki values (Dixon analysis), reactions at 37 C were
initiated by the addition of PAM (0.03-0.06 µg) into 2700 ì l of 100 mM MES/NaOH pH
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6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001 % (v/v) Triton X-100, 10 µg/ml bovine
catalase, 1.0 µM Cu (NO3)2, 5.0 mM sodium ascorbate, 9 mM N-acetylglycine, and
inhibitor (1.0-200 ìM). Rates were monitored, recorded, and alayzed in Microsoft Excel.

Copper Chelating Experiment
Reactions at 37 C were initiated by the addition of 0.05

µg PAM into 500 ì l of

100 mM MES/NaOH pH 6.0, 30 mM NaCl, 1.0% (v/v) ethanol, 0.001 % (v/v) Triton X100, 10 µg/ml bovine catalase, 1.0 µM Cu (NO3)2, and 5.0 mM sodium ascorbate. Three
dansyl Tyr-Val-Gly concentrations of 4µM, 10µM, and 20µM were tested. S-(4methylthiobenzoyl)thioglycolic acid was tested at 12 µM and EDTA was tested at 30
µM. Both compounds were tested at the three different N-dansyl Tyr-Val-Gly
concentrations. Aliquots of 50 µl were taken at 5, 10, 15, 20, and 25 minutes. The
reaction aliquot was quenched with 10 µl of 6 % (v/v) trifluoroacetic acid in a HPLC
microvial to terminate the PAM reaction. The aliquots were assayed for N-dansyl-TryVal-Gly and N-dansyl-Try-Val-NH2 on a reverse-phase C18 column (100 mm x 4.6 mm,
5 µm particles, 120 pore). The mobile phase for the separation consisted of 100 mM
sodium acetate, 55% deionized water and 45% acetonitrile.

Molecular Modeling
HyperChem 7.5 was used for performing molecular modeling. Substrates and
inhibitors were calculated to their lowest energy states using Amber 99. The compounds
were then inserted into the active site of PHM in both the phenyl ring in (substrate-like)
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and the phenyl ring out confirmations. The lowest energy conformation was determined
by the method of Polak-Ribiere. The energies were compared to the energy of the
unbound reduced enzyme to determine the stability of the enzyme-inhibitor complex.

RESULTS AND DISCUSSION
PAM substrates and inhibitors
Results from this study (Table 2) suggest that compounds with sulfanyl type
groups, such as S-(phenylthioacetyl)thioglycolic acid and S-(N-phenylthiocarbamoyl)-3mercaptopropionic acid, appear to bind more tightly then compounds with hydrogen or
oxygen. (Phenylthio)acetic acid does not have a sulfanyl group and has a much higher
Ki. Substrates with oxygen have a much higher KM then those with sulfanyls. This trend
can be seen when comparing the KM of N-(phenylthiopropionyl)glycine to N-(6phenylhexanoyl)glycine (Table 3). Since sulfur has a higher electron density than
oxygen, it is possible that this atom interacts with the two coppers in the active site. In
addition, since redox chemistry is necessary for the reaction to proceed and altering the
coordinating sphere of copper ions could dramatically affect the reduction potentials, the
sulfur atoms could interfere with electron transfer within the enzyme.
Another class of compounds that exhibit tight binding contains other functional
groups on the benzene ring. For example, methyl groups in the para position exhibit tight
binding. S-(4-Methylthiobenzoyl)thioglycolic acid has this moiety and has the low Ki of
3.5 ìM.

4-Ethylhippuric acid and 4-propionylhippuric acid are two substrates with
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Inhibitor

Ki,app,
(µM)

S

Inhibitor

39 ±
5.2
S

S

3.6 ±
0.4

S

COOH

S-(Thiobenzoyl)thioglycolic acid
S

Ki,app,
(µM)

N
COOH
H
N-(Phenylthioacetyl)alanine

3.5 ±
0.39

S

COOH

COOH

20 ±
5.8

S
N

S-(4-Methylthiobenzoyl)thioglycolic
acid

S

4-Cyano-4-methyl-4-thiobenzoyl-sulfanylbutyric acid

110 ±
12
S

COCH2CH3

N
H

S

7.9 ±
2.8

54 ±
4.0

O

COOH

N
H

O

COOH

N-Glycolic Acid phenyl urethane

S-(3-Phenylthiopropionyl)thioglycolic
acid

S

22 ±
2.6
N
H

COOH

S-(N-Phenylthiocarbamoyl)thioglycolic acid

2

O

11 ±
1.9
S

9.4 ±
0.8
S

COOH

S
N
H

S
COOH
S-(Phenylthioacetyl)thioglycolic
acid
S

2

S-(N-Phenylthiocarbamoyl)-3mercaptopropionic acid

S-(4Methylthiobenzoyl)thioglycolic acid
ethyl ester

S

3.3 ±
0.88

S

COOH

380 ±
36

COOH

HS
(D,L)-Thiorphan
S
COOH

(Phenylthio)acetic acid

29 ±
3.4

S
H3C

NO2
(2-Nitrophenylthio)acetic acid

COOH

C

0.54 ±
0.045

10

S

S-(Thiolauroyl)thioglycolate

Table 2- Summary of inhibitors examined and corresponding inhibition constants.
Inhibition constants were calculated by Dixon analysis.
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Substrate

VMAX,app
(µmoles/min
/mg)
6.5 ± .063

(V/K)app
(M-1s-1)

Relative
(V/K)app

6.2 × 103

1.0

350 ± 70

7.6 ± 0.65

2.7 × 104

4.4

1162.1 ±
166.45

2.9 ± 0.2

2.8 × 103

0.45

38 ± 15

1.3 ± 0.11

4.3 × 104

6.9

1207.3 ±
157.64

4.1 ± 0.3

4.1 × 103

0.66

96 ± 14

8.2 ± 0.53

1.1 × 105

17

104.84 ±
9.3273

6.4 ± 0.2

1.2 × 105
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KM,app
(µM)
1300 ±
36

O
N
H

COOH

Hippuric acid
O
N
H

N
H

COOH

N-Phenylhydantoic acid
O
N
H

COOH

4-Ethylhippuric acid
S
N
H

2

COOH

N-(Phenylthiopropionyl)glycine
O
N
H

COOH

2

4-Propionylhippuric Acid
O
N
H

5

COOH

N-(6-Phenylhexanoyl)glycine
O

7

N
H

COOH

N-(8-Phenyloctanoyl)glycine
Table 3- Summary of substrates examined and corresponding kinetic constants.
Kinetic constants were calculated using Michaelis-Menton calculations.
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extended hydrocarbon chains in the para position. Interestingly this did not seem to
affect the binding affinity. In addition, functional groups at the ortho position
dramatically increase the binding affinity. (2-Nitrophenylthio)acetic acid has a 12-fold
tighter binding affinity to (phenylthio)acetic acid.
The length of the hydrocarbon chain also affects the binding affinity of the
inhibitors. S-(Thiobenzoyl)thioglycolic acid, S-(phenylthioacetyl)thioglycolic acid, and
S-(3-phenylthiopropionyl)thioglycolic acid have the same structure with the exception of
the hydrocarbon chain before the sulfanyl group. The trend in binding affinity shows that
in this group of compounds, the ideal length for inhibition is two carbon groups prior to
the sulfanyl. The substrates N-(6-phenylhexanoyl)glycine and N-(8phenyloctanoyl)glycine show that PAM prefers a lengthy hydrocarbon chain since their
KM are 13-fold lower then hippurate.

Figure 7- Different energies that can be predicted by molecular modeling.
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Molecular modeling was performed to understand the relationship between Ki and
binding energies of the compounds to better understand the structure activity of the PAM.
There are three types of energies to consider when determining the total free energy of a

a.) ÄG = ÄG
b.) ÄG

pocket

docking

+ ÄG

channel

+ ÄG

pocket

= ÄHpocket - TÄSpocket

Figure 8- a.) The formula to calculate the total free energy for the complete docking
of a compound into the active site of PHM. b.) The formula for calculating the free
energy for the pocket energy. Hyper Chem 7.5 calculates the pocket enthalpy.

compound in the active site of PHM (Figure 7). The first of these energies is the docking
energy. This is the energy for the compound to enter the active site. The second is the
channel energy, which is the energy of the compound to move through the active site
channel to get to the binding site. The last is the pocket energy once inside the binding
pocket (Figure 8a). The program used in this study, Hyperchem 7.5, is capable of
calculating the channel enthalpies and the pocket enthalpies, which can be used to
calculate the channel and pocket energies (Figure 8b). A more sophisticated software
program is required to calculate the docking enthalpies and actually proposing a specific
path that the compound travels from entering the channel to binding into the pocket of the
enzyme. For the preliminary studies only the pocket enthalpies were calculated for
known substrates and inhibitors of PAM.
The results from the molecular modeling can be seen in Table 4. The enthalpy of the
reduced form of PHM without a substrate or inhibitor in the binding pocket was
calculated. The enthalpies of the substrates and inhibitors were subtracted from the
unbound enthalpy to give the pocket enthalpy. The stability of a compound in the
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Inhibitor

Bond
Energy
(kJ/mol)
-10.88

S
S

Inhibitor

S

COOH

S-(Thiobenzoyl)thioglycolic acid
S
S

Bond
Energy
(kJ/mol)
-16.91

N
COOH
H
*N-(Phenylthioacetyl)alanine

-20.92

S

COOH

COOH

-18.87

S
N

*S-(4-Methylthiobenzoyl)thioglycolic
acid

S

*4-Cyano-4-methyl-4-thiobenzoyl-sulfanylbutyric acid

-17.91
S

COCH2CH3

N
H

S

-15.11

-10.81

O

COOH

N
H

O

COOH

*N-Glycolic Acid phenyl urethane

S-(3-Phenylthiopropionyl)thioglycolic
acid

S

-38.37
N
H

COOH

*S-(N-Phenylthiocarbamoyl)thioglycolic acid

2

O

-15.13
S

-21.51
S

COOH

S
N
H

S
COOH
S-(Phenylthioacetyl)thioglycolic
acid
S

2

*S-(N-Phenylthiocarbamoyl)-3mercaptopropionic acid

S-(4*Methylthiobenzoyl)thioglycolic acid
ethyl ester

S

-16.51

S

COOH

-9.99

COOH

HS
(D,L)-Thiorphan
S
COOH

*(Phenylthio)acetic acid

-11.5

S
H3C

NO2
(2-Nitrophenylthio)acetic acid

COOH

-19.07

C
10

S

* S-(Thiolauroyl)thioglycolate

Table 4- Summary of pocket enthalpies. The * represents compounds that bind
substrate-like.
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binding site increases as calculated pocket enthalpy decreases. The substrates and
inhibitors were calculated inside the binding site of PHM in two conformations. The
phenyl group was placed going into the pocket, which is substrate-like, and placed
coming out of the pocket. The inhibitors showed stability in both conformations,
Inhibitor

Bond
Energy
(kJ/mol)
-10.88
(39)

S
S

Substrate

O

COOH

N
H

S-(Thiobenzoyl)thioglycolic acid
S

O

COOH

N
H

N
H

-21.51
(9.4)

-11.96
(920)

O

COOH

N
H

2

S-(3-Phenylthiopropionyl)thioglycolic
acid

COOH

N-(Hydrocinnamoyl)glycine
-10.81
(54)

O

COOH

N-(Phenylthioacetyl)glycine

2

N
H

-37.30
(24)

S

S
COOH
S-(Phenylthioacetyl)thioglycolic
acid

O

COOH

N-(Phenylacetyl)glycine
-15.11
(7.9)

S

-14.95
(150)

O

S
COOH
S-(Phenylthioacetyl)thioglycolic
acid

S

COOH

4-Methylhippuric acid
-15.11
(7.9)

S

-13.27
(1800)
N
H

S-(4-Methylthiobenzoyl)thioglycolic
acid

S

COOH

Hippuric acid
-20.92
(3.5)

S

Bond
Energy
(kJ/mol)
-11.00
(1300)

-12.14
(350)

O
N
H

COOH

N
H

COOH

N-Phenylhydantoic acid
N-Glycolic Acid phenyl urethane
Table 5- Comparison of inhibitor and substrate pocket enthalpies and binding constants.
The number in ( ) represents either Ki for inhibitors or KM for substrates in ìM.
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depending on what substituents were on the phenyl ring. All of the substrates showed the
preference of the phenyl ring going into the binding pocket.
There is a correlation between pocket enthalpies and the binding constants. As a
general trend, if the Ki of an inhibitor is less then 10 ìM, the enthalpy predicted will be <
-15. The active site contains two copper atoms, CuH and CuM, which cycle through CuII
and CuI redox states during catalysis. The two coppers are non-equivalent, CuM being the
oxygen-binding site and CuH an electron-donor site. All of the compounds gravitated
toward CuM. This would suggest that there is an important interaction going on with this
copper site.
The enthalpies of some substrates and their corresponding inhibitors can be seen
in Table 5. The pocket enthalpies of the substrates seem to coincide with their KM’s, with
the exception of 4-methyl hippuric acid. It shows more stability then hippuric acid inside
the binding site even though it has a higher KM. This does follow the trend of the
inhibitors in which the hippuric acid derivative is a much worse inhibitor then the 4methyl hippuric acid derivative. When the carbonyl is changed to a sulfanyl the
compound becomes more stable in the binding pocket.
There are a few compounds where the pocket enthalpies and the binding constants
do not seem to correlate. (Phenylthioacetic) acid has a high binding constant, but its
pocket enthalpy does not seem to be that much less then other compounds with lower
binding constants. This compound may have a low docking enthalpy, so it can get into
the channel, but may not bind to the substrate site well. This would effectively block
substrates from binding to the enzyme. Based on the pocket enthalpy from 4-cyano-4methyl-4-thiobenzoyl-sulfanyl-butyric acid, it would be expected that it would be a tight
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binding inhibitor, but it does not appear to be. This compound may not bind well to the
active site (high docking enthalpy), but if it were able to access the substrate site, the
enzyme-inhibitor complex would have a relatively low Kdissociation. The same thing could
be happening with thiorphan. Another possible reason for the differences in pocket
enthalpies and binding constants may be that the compounds are binding to a different
site on the enzyme other then the active site.

In any case this shows that there is a high

probability that there is more then one way a compound binds into the active site of
PHM.
When the substrates were tested using the dansyl assay and the oxygen
consumption assay, the binding constants were found to be relatively close except for two
compounds. 4-Ethylhippuric acid and 4-propionylhippuric acid have roughly a 4-fold
difference (Table 4) in KM. This may be due to an unforeseen PAL inhibition or possible
substrate inhibition. This may also indicate that the KM determined by oxygen
Substrate

O
N
H

KM,app
Oxygen
consumption
(µM)
1200 ± 170

350 ± 38

1200 ± 160

COOH

4-Ethylhippuric Acid
O
N
H

KI,app
Dansyl
Assay
(µM)
370 ± 37

COOH

2

4-Propionylhippuric Acid

Table 6- This is a comparison of KM value from the oxygen consumption assay and the Ki
value from the dansyl assay that show significant differences.
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consumption is greater then the true Kd.

Copper chelating experiment
An experiment was performed to determine if the sulfur-containing inhibitors
inhibit PAM by competing with substrate for the active site or if they simply depleted
copper from the enzyme through chelation. If the inhibitors were depleting the enzyme
of copper, the resulting apo-enzyme would be catalytically inactive and could not
generate product from substrate at any concentration. On the other hand, if the
compounds inhibited the enzyme, increasing the substrate concentration would out
compete the inhibitor and product formation would increase as the as the substrate
concentration increased. As seen in Graph 4, the inhibitor, S-(4methylthiobenzoyl)thioglycolic acid, showed an increase of product formation, as the
substrate concentration was increased. To ensure that this result was accurate, the amount
of inhibitor used was 3 times the Ki. There was no product formation when EDTA was
added to the reaction.

Determination of KM and VMAX values for N-dansyl-Tyr-Val-Gly as a function of inhibitor
concentration
The results from a full inhibition study of S-(3-phenyl thiopropionyl) thioglycolic
acid (Graph 5) indicated mixed inhibition, which was contradictory to previous models.
The Kis calculated was 25 ± 10 ìM and the Kii was calculated to be 0.31 ± 0.18ìM. The
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Graph 4- Plot of product formation vs. substrate concentration in 4, 10, and 20 ì M of
EDTA and S-(4-methylthiobenzoyl)thioglycolic acid (Ki = 3.5 ì M).

Kis found in this experiment was similar to the Ki calculated in previous experiments.
The theory was that the inhibitors were competitive. To verify the finding of mixed-type
inhibition, a known competitive substrate was tested in the dansyl assay. The results
from the experiments with N-octanoyl glycine (Graph 6) showed competitive inhibition
with the N-dansyl-Tyr-Val-Gly with a Kis of 550 ± 64 ìM, which is similar to the KM
measured by O2 consumption (200 ± 10 ìM ).
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Graph 5- Full kinetic study of S-(3-phenyl thiopropionyl) thioglycolic acid.

Conclusion
The kinetic constants of several substrates and inhibitors of PAM were
determined. Several inhibitors were shown to have inhibition constants in the low
micromolar range and one, S-(thiolauroyl)thioglycolate exhibited a submicromolar
inhibition constant of 0.54 ± 0.0045ìM. Through molecular modeling, a preliminary
trend in the Ki values was found. Inhibitors with a Ki less then 10 ìM show a pocket
enthalpy of less then –15.0 kJ/mol. Proposed molecules can be placed in the binding site
of PHM to predict the Ki. The modeling also shows evidence of more then one binding
mode. Some of the inhibitors follow the binding pattern of substrate, and other prefer to
be oriented in the reverse position. The full kinetic study of S-(3-phenyl thiopropionyl)
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thioglycolic acid supports the idea that some of these inhibitors exhibit more then one
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Graph 6- Full kinetic study of N-octanoyl glycine

binding mode to PAM. S-(3-phenyl thiopropionyl)thioglycolic acid is one of the
inhibitors that shows a preference for the reverse conformation. Further modeling should
be performed on additional compounds to learn more about the structure-activity
relationship between binding compounds and PHM. Determination of channel enthalpies
and docking enthalpies will also help show the pathway of binding. The inhibitors with
the lowest inhibition constant were tested for cancer growth inhibition.
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Chapter Three
Prostate Cancer Testing

INTRODUCTION
DU 145 Anti-Proliferation Assays
PAM is suspected to play an important role in androgen-independent prostate
cancer proliferation. Two androgen-independent prostate cancer cell lines often used in
cancer research are the DU 145 and PC-3 cells. The experiments discussed in this
chapter utilize DU 145 androgen-independent cells to probe the effects of PAM inhibitors
on cell growth.
Trypan blue stains only dead cells and thus, is used to assay for cell viability.
This assay finds wide utilization in many types of cancer research (Lee2001). Another
assay used to assay cell viability is dependent upon the production of NADH, a metabolic
product of living cells. NADH production drives the reduction of a tetrazolium (MTT,
being frequently employed) to an intensely colored formazan (Rocchi 2001).
S-(4-Methylthiobenzoyl)thioglycolic acid and S-(phenylthioacetyl)thioglycolic
acid were chosen for this study based on low inhibition constants and stability. S-(NPhenylthiocarbamoyl)thioglycolic acid and S-(N-phenylthiocarbamoyl)-3mercaptopropionic acid exhibit lower inhibtion constants, but cyclize at pH values < 10.
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S-(N-Phenylthiocarbamoyl)thioglycolic acid has a t1/2 of 30 minutes and S-(Nphenylthiocarbamoyl)-3-mercaptopropionic acid has a t1/2 of 8 hours at pH less than 10.
N- (4-Hydroxyphenyl) retinamide (4-HPR) was used as a control. This is a
known growth inhibitor of DU 145 cells. The aminophenol ring and the long alkyl chain
are two important structures on this compound that are key for drug-cell contact
(Takahashi 2002). The target enzyme that 4-HPR inhibits is not known.

EXPERIMENTAL PROCEDURES
Materials
0.05% Trypsin/ 0.53 mM EDTA w/o Ca, Mg, and NaHCO3, minimum essential
medium Eagle (EMEM), and phosphate buffered saline (PBS) were from Cellgro.
Trypan blue (0.4% units) was from Life Technologies. Fetal bovine serum (FBS) was
obtained from Atlanta Biologicals. Hank’s Balanced Salt (HBS) was obtained from ICN
Biomedicals. DU 145 prostate cancer cell line was obtained from ATCC. Sodium
pyruvate and sodium bicarbonate were obtained from Fisher. Cell culture was carried out
in a Nuaire flow hood. Samples were observed under a Nilon TMS phase-contrast
microscope.

Cells and cell culture
The DU 145 prostate cancer cells were grown in Eagle’s minimum essential
medium (EMEM) with Earle’s Salts (CaCl2, KCl, MgSO4, and Na2HPO4) and 2 mM
glutamine. The growth media also contained, 1.0 mM sodium pyruvate, 0.1 mM
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nonessential amino acids (contains all 20 amino acids), 1.5 g/L sodium bicarbonate, 10%
FBS, 10,000 U/ml penicillin, and 10,000 ì g/ml of streptomycin (Papsidero 1981).

Anti-proliferation assay of S-(4-methylthiobenzoyl)thioglycolic acid
DU 145 cells were grown to 80% confluency in media as described. The cells
were then trypsonized, counted, and diluted to give 50,000 cells per well. The cells were
allowed to attach to the bottom of the wells for 24 hours. The media was replaced and S(4-methylthiobenzoyl)thioglycolic acid was added to the media in concentrations of 0.1
mM, 0.5 mM, and 1 mM. S-(4-methylthiobenzoyl)thioglycolic ethyl ester was tested at a
concentration of 0.1 mM as a comparison. Cells were then counted at 24, 48, 72, and 96
hours. For each time point, the media was removed the cells and the cells were washed
twice with PBS. Trypsin/EDTA was added to detach cells. Media (2 ml) was added to
each well, mixed, and removed. A sample from each well was taken out and Trypan blue
and HBS were added. The viable and non-viable cells were counted on a hemacytometer.
Viable cells appeared clear and non-viable cells appeared blue (Lee 2001).

Anti-proliferation assay of S-(phenylthioacetyl)thioglycolic acid
DU 145 cells were grown to 80% confluency as described. Cells were
trypsonized, counted, and diluted to give 50,000 cells per well. The cells were allowed to
attach to the bottom of the wells for 24 hours. The media was replaced and S(phenylthioacetyl)thioglycolic acid was added to the media in concentrations of 0.5 mM,
1 mM, and 2 mM. 4-HPR was tested at a concentration of 0.01 mM as a positive control.
Cells were then counted at 8, 24, 48, 72, and 96 hours. For each time point, the media
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was removed the cells and the cells were washed twice with PBS. Trypsin/EDTA was
added to detached cells. Media (2 ml) was added to each well, mixed, and removed. A
sample from each well was taken out and Trypan blue and HBS were added. The viable
and non-viable cells were counted on a hemacytometer. Viable cells appeared clear and
non-viable cells appeared blue (Lee 2001).

RESULTS AND DISCUSSION
Anti-proliferation assay of S-(4-methylthiobenzoyl)thioglycolic acid
The results of the anti-proliferative assay with S-(4-methylthiobenzoyl)
thioglycolic acid can be seen in Graph 7. S-(4-Methylthiobenzoyl)thioglycolic acid does
inhibit the growth of androgen-independent prostate cancer, but only at relatively high
concentrations (1.0mM). There is only a significant decrease of growth at a
concentration of 1 mM for S-(4-methylthiobenzoyl)thioglycolic acid. This concentration
is likely to be too high to be of any practical use as an anti-cancer drug. To counter this
problem, the ethyl ester of S-(4-methylthiobenzoyl)thioglycolic acid was tested. It was
thought that the ethyl ester would make the compound more hydrophobic and would
facilitate transport across the cell membrane into the cell. Once inside the cell, an
esterase would hydrolyze off the ethyl ester leaving S-(4-methylthiobenzoyl) thioglycolic
acid. As the results show, the ethyl ester was no more effective then the free acid as an
anti-proliferative agent. Since the Ki of the ethyl ester is ~30-fold higher, these data
suggest that the ethyl ester is more effective in crossing the cell membrane since the
relative potency as an anti-proliferative is approximately as the same as the free acid.
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Graph 7- Anti-proliferative assay of 4-methylthiobenzoylthioglycolic acid on DU 145 prostate cancer
cells. The ethyl ester of this compound was also tested for comparison. Cells were grown to 50,000
cells per well and then treated or not treated with various concentrations of 4-methylthiobenzoyl
thioglycolic acid or its ethyl ester. Growth was measured at 24, 48, 72, and 96 hours.

Anti-proliferation assay of S-(Phenylthioacetyl)thioglycolic acid
Graph 8 shows the results of the anti-proliferative assay with S(phenylthioacetyl)thioglycolic acid. There is a significant inhibition of growth with this
compound at concentrations 1.0 mM. Again, the concentrations exhibiting anti proliferative activity preclude its use as an anti-proliferative in humans. In this
experiment, a known growth inhibitor of DU 145 cells was tested as a
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Graph 8- Anti-proliferative assay of S-(phenylthioacetyl)thioglycolic acid on DU 145 prostate cancer
cells. 4-HPR was tested as a positive control. Cells were grown to 50,000 cells per well and then
treated or not treated with various concentrations of S-(phenylthioacetyl)thioglycolic acid or 4-HPR.
Growth was measured at 8, 24, 48, 72, and 96 hours.

positive control. 4-HPR completely inhibits cell growth in 48 hours at a concentration of
10 ìM, consistent with previously published results (Graph 8).
S-(4-Methylthiobenzoyl)thioglycolic acid and S-(phenylthioacetyl)thioglycolic
acid were also tested since they showed the lowest inhibition constant against PAM.
Since 4-HPR completely stopped the growth of the DU 145 cells and S-(4methylthiobenzoyl) thioglycolic acid and S-(phenylthioacetyl)thioglycolic acid did not, it
does not seem necessary to test the less potent inhibitors.
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Conclusion
The anti-proliferative assays on S-(4-methylthiobenzoyl)thioglycolic acid and S(phenylthioacetyl)thioglycolic acid did show a significant inhibition of growth, but only
at high concentrations. The high concentration needed to effectively treat androgenindependent prostate cancer would require massive dosages if used to treat patients.
Perhaps a compound with a lower inhibition constant would be more effective against the
cells. These data suggest that a PAM inhibitor could be useful as an anti-proliferative
drug, but compounds > 103-fold more potent must be developed for anti-PAM drugs to
even be considered for clinical use.
The kinetic constants are known for many substrates and inhibitors of PAM.
Though none of the compounds bind tight enough to PAM to completely stop the growth
of androgen-independent prostate cancer, they did show that they exhibit antiproliferative activity. This shows that there is a potential that PAM inhibitors of
considerably higher potency (lower Ki values) might have clinical relevance.
Since only the S-(thiolauroyl)thioglycolate bound at submicromolar
concentrations, a new design should be developed. Instead of having substrate-like
inhibitors, product-like or transition state analogs should be made. Preliminary data on
some product-like inhibitors have showed potential in attaining this goal. More extensive
kinetic studies on all of the inhibitors are required to fully understand the complexities of
their interaction with PAM. Such data are necessary to completely exploit the specific
interactions of this series of compounds with PAM to develop second-generation
compounds that bind more tightly to PAM
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More intensive molecular modeling of the inhibitors into the active site should be
done. With the kinetic constants of these compounds and others previously done, a better
database can be constructed for future compound development. The database will help
predict which inhibitors will be most potent.
The next step in the anti-proliferative assays is to see if the compounds are
actually inhibiting PAM. To do this, the amount of a particular amidated peptide
hormone should be determined. If the compound is targeting PAM, there should be
significantly less amount of the á-amidated hormone in the treated cancer cells compared
to controls not exposed to the compound. The ethyl esters of current compounds need to
be tested for esterase activity to see if they are getting cleaved within the cell. If they are
not, then perhaps another functional group can be attached to the compounds to facilitate
the crossing of the cell membrane. For example a benzyl ester might yield more
promising results.
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